Results 171 to 180 of about 3,014,077 (337)

“Therapies Through Gut:” Targeted Drug Delivery for Non‐Gastrointestinal Diseases by Oral Administration

Advanced Healthcare Materials, EarlyView.
Schematic illustration of the mechanism of targeted delivery of nanoparticles including 1) paracellular, 2) endolysosomal escape, 3) receptor mediated endocytosis, and 4) M cell mediated transport for non‐GI diseases by oral administration such as atherosclerosis, cancer, diabetes, and brain diseases. Abstract Oral drug delivery is a promising approach
Subarna Ray, Shehzahdi S. Moonshi, Hang Thu Ta   +2 more
wiley   +1 more source

Conjugação de controle isotípico para citometria de fluxo Conjugation of isotypic control for flow cytometry

Revista Brasileira de Hematologia e Hemoterapia, 2007
Juliana Pereira
doaj   +1 more source

Potential inappropriate medications and drug-drug interactions in adverse drug reactions in the elderly: a retrospective study in a pharmacovigilance database. [PDF]

Front Pharmacol
Jiang H, Lin Y, Ren W, Lu L, Tan X, Lv X, Zhang N.   +6 more
europepmc   +1 more source

Radiation‐Resistant Bacteria Deinococcus radiodurans‐Derived Extracellular Vesicles as Potential Radioprotectors

Advanced Healthcare Materials, EarlyView.
Deinococcus radiodurans‐derived extracellular vesicles (R1‐EVs) provide radioprotection against total‐body irradiation‐induced acute radiation syndrome in mice. R1‐EVs mitigate oxidative damage by scavenging free radicals, promoting intestinal repair, enhancing hematopoietic function, and modulating immune responses. This study highlights the potential
Jeong Moo Han, Godfrey Mwiti, Seo‐Joon Yeom, Jaeyoon Lim, Woo Sik Kim, Sangyong Lim, Seung‐Taik Lim, Eui‐Baek Byun   +7 more
wiley   +1 more source

Common haematological malignancies in Northeastern Nigeria: a multi-centre study of their pattern, distribution and treatment challenges. [PDF]

Front Oncol
Dachi RA, Mustapha FG, James J, Pindiga KM, Ezenkwa US, Yusuf MO, Yuguda S, Suleiman DE.   +7 more
europepmc   +1 more source

Novel Less Toxic, Lymphoid Tissue‐Targeted Lipid Nanoparticles Containing a Vitamin B5‐Derived Ionizable Lipid for mRNA Vaccine Delivery

Advanced Healthcare Materials, Volume 14, Issue 7, March 14, 2025.
The top‐performing lipid nanoparticle, incorporating a novel ionizable lipid derived from vitamin B5, demonstrates high mRNA transfection efficiency, low toxicity, favorable stability, targeted delivery to lymphoid tissues, and high immunogenicity, showing promise as a carrier for mRNA vaccines for infectious diseases and cancer.
Soyeon Yoo, Muhammad Faisal, Seo‐Hyeon Bae, Kounghwa Youn, Hyo‐Jung Park, Sung Pil Kwon, Il Kwon Hwang, Jisun Lee, Hyeong Jun Kim, Jae‐Hwan Nam, Gyochang Keum, Eun‐Kyoung Bang   +11 more
wiley   +1 more source

Non-Attendance in Hospital Appointments Based on Data From the Entire Region of Southern Denmark: Descriptive Analyses and Predictive Factors. [PDF]

Clin Epidemiol
Nørgård BM, Iachina M, Ammentorp J, Schwalbe DM, Waidtløw KY, Richardt L, Sodemann M.   +6 more
europepmc   +1 more source

Glepaglutide‐Loaded Foam for the Induction of Mucosal Healing in the Treatment of Inflammatory Bowel Disease

Advanced Healthcare Materials, Volume 14, Issue 7, March 14, 2025.
Glepaglutide (GL), a GLP‐2 analog with an extended half‐life (50 h), is currently undergoing clinical trials for patients with short bowel syndrome. GL requires subcutaneous injection, which poses challenges for potential patient compliance. To address this challenge, we loaded GL into a rectal foam formulation using CO2 as a permeation enhancer to ...
Wunan Zhang, William Van den Bossche, Hafsa Yagoubi, Espoir K Kambale, Khadija Wahni, Tanya Saxena, Léo Guilbaud, Tom G. Moreels, Joris Messens, Ana Beloqui   +9 more
wiley   +1 more source

From clinical trials to informing clinical decision-making: a review of patient-reported outcomes in nononcology medicines approved by the European Medicines Agency (2018-2022). [PDF]

Front Pharmacol
Sauchelli S, Levy C, Gnanasakthy A, Dave V, Doward L, Fitzgerald KA, Carson R.   +6 more
europepmc   +1 more source

Synthetic Bilirubin‐Based Nanomedicine Protects Against Renal Ischemia/Reperfusion Injury Through Antioxidant and Immune‐Modulating Activity

Advanced Healthcare Materials, Volume 14, Issue 7, March 14, 2025.
BX‐001N, a polyethylene glycol‐conjugated bilirubin 3α nanoparticle, is the first GMP‐grade, synthetic bilirubin‐based nanomedicine. It effectively attenuates acute renal injury, facilitates subacute renal recovery, and suppresses chronic fibrosis after renal ischemia/reperfusion injury via anti‐oxidant and immune‐modulating activity.
Ji‐Jing Yan, Hyunjin Kim, Bomin Kim, Honglin Piao, Joon Young Jang, Tae Kyeom Kang, Wook‐Bin Lee, Dohyeon Kim, Seunghyun Jo, Duckhyang Shin, Sharif MD Abuzar, Myung L. Kim, Jaeseok Yang, Sangyong Jon   +13 more
wiley   +1 more source